



Targeted Therapy in Cancer Ovary

Essay

*Submitted for Partial Fulfillment of Master Degree
in Clinical Oncology and Nuclear Medicine*

By

Sharehan Ibrahim Kotb

M.B.B.Ch

Under Supervision of

Prof. Dr. Nivine Mahmoud Ahmed Gado

Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University

Assist. Prof. Dr. Hesham Ahmed Elghazaly

Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University

Dr. Khalid Kamal Eldin Elghonemy

Lecturer of Clinical Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University

**Faculty of Medicine
Ain Shams University
2013**



Allah


First and above all, I pray thanking you for your great Blessing, giving me the effort to complete and achieve this work,

*I would like to express my deep gratitude, thanks, and respect to our eminent **Prof. Dr. Nivine Mahmoud Ahmed Gado**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University for her enthusiastic support, encouragement valuable scientific advices, I'm so proud to complete this work under her supervision. May God bless her.*

*I would like to express my thanks and admiration to **Assist. Prof. Dr. Hesham Ahmed Elghazaly**, Assistant Professor of Clinical Oncology and Nuclear Medicine Faculty of Medicine, Ain Shams University for his kind and meticulous supervision, support, help, valuable supervision all through the work,*

*I am extremely grateful to **Dr. Khalid Kamal Eldin Elghonemy**, Lecturer of Clinical Oncology and Nuclear Medicine Faculty of Medicine, Ain Shams University for his kind supervision, encouragement, wonderful support and meticulous revision of this work,*

*I am really honored by the presence of **Prof. Dr. Ahmed Abd El Maaboud Zein**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Cairo University, and **Prof. Dr. Ali Azmy**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine – Ain Shams University.*



Sharehan Ibrahim Kotb



فَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة (الآية ٣٢)

List of Contents

Subject	Page
List of Abbreviations	I
List of Tables	V
List of Figures	VII
Introduction and Aim of the Work	1
Review of Literature	
Chapter (1): Epidemiology Etiology & Risk Factors	6
Chapter (2): Pathological Subtypes and prognosis	15
Chapter (3): Screening and Diagnosis	28
Chapter (4): Molecular Biology of Ovarian Cancer	
Signaling Pathways for Intervention	36
Chapter (5): Treatment Options of Ovarian Cancer	61
Chapter (6): Targeted Therapy in Ovarian Cancer	78
Chapter (7): Toxicities of Targeted Therapy and	114
Management Strategies	
Summary	142
References	145
Arabic Summary	\

List of Abbreviations

Abb.	Meaning
AEs	Adverse events
AFP	Alpha-fetoprotein
BEV	Bevacizumab
BFGF	Basic fibroblast growth factor
BMI	Body mass index
CCC	Clear cell carcinoma
CDK	Cyclin-dependent kinase
CI	Confidence interval
CK7	Cytokeratin 7
CR	Complete remission
CREB	cAMP response element-binding protein
CSF	Colony stimulating factor
CT	Computerized tomography
CVC	Cancer Vaccine Collaborative
CWG	Cytokine Working Group
CXR	Chest X Ray
DCs	Dendritic cells
DFS	Disease free survival
DHFR	Dihydrofolate reductase
DOX	Doxorubicin
EC	Endometroid carcinoma
EGFR	Epidermal growth factor receptor
EORTC	European Organization for Research and Treatment of Cancer
EPIC	European Prospective Investigation into Cancer and Nutrition

Abb.	Meaning
EPIC	European prospective investigation into cancer and nutrition
ER	Estrogen receptor
FDA	Food and Drug Administration
FDG-PET/CT	Fluoro-D-glucose positron emission Tomography/Computerized tomography
GCIG	The Gynecologic Cancer Intergroup
GEM	Gemzar
GIP	Gastrointestinal perforation
GLUT-1	Glucose transporter 1
GOG	Gynecologic Oncology Group
HCG	Human chorionic gonadotropin
HD	High dose
HFSR	Hand foot skin reaction
HGSC	High-grade serous carcinomas
HRT	Hormone replacement therapy
Hs	Hours
I.V.	Intravenous
IARC	International Agency for Research on Cancer
IARC	International Agency for Research on Cancer
IGF 1	Insulin growth factor 1
IGFBP 1-7	Seven high-affinity binding proteins
IR	Insulin receptor
IU	International Unit
Kg	Kilogram
LC	Local control
LDH	Lactate dehydrogenase
LGSC	Low grade serous carcinoma

Abb.	Meaning
LND	Lymph node dissection
LRF	Locoregional failure
MAPK	Mitogen activated protein kinase
MC	Mucinous carcinoma
MMAE	Monomethyl auristain E
MMPI	Matrix metalloproteinase inhibitors
MRI	Magnetic resonance imaging
mTOR	Mammalian target of rapamycin
mTORC1	Mammalian target of rapamycin complex 1
NCCN	National Comprehensive cancer network
NSAIDS	Non-steroidal anti-inflammatory drugs
NWLCN	North west London Cancer Network
OCP	Oral contraceptive pills
ORR	Overall response rate
OS	Overall survival
P53	Protein 53
PARPI	Polyadenosine ribose pathway inhibitors
PDGF	Platelet derived growth factor
PI3K	Phosphoinositide 3-kinase
PIP2	Phosphatidylinositol-4,5-bisphosphate
PR	Progesteron receptor
PR	Partial remission
RECIST	Response Evaluation Criteria In Solid Tumors
RR	Relative risk
RT	Radiation therapy
S.C.	Subcutaneous
SAM	S-adenosylmethionine
SD	Stable disease

Abb.	Meaning
SEER	Surveillance, Epidemiology and End Results
SWOG	Southwest Oncology Group
TAA	Tumor-associated antigen
TILs	Tumor-infiltrating lymphocytes
TKIs	Tyrosin kinase inhibitors
TTP	Time to progression
UK	United kingdom
US	Ultrasound
VEGF	Vascular endothelial growth factor
VEGFR-1	Vascular endothelial growth factor-1
Vs.	Versus
WHO	World health organization
XIAP	X-linked inhibitor of apoptosis protein

List of Tables

Table No.	Title	Page
Table (1)	Incidence Rates by Race	6
Table (2)	Death Rates by Race	7
Table (3)	Relative Risk for Ovarian Cancer by Parity and Duration of Oral Contraceptive	9
Table (4)	According to SEER, the types of ovarian cancers in women age 20+	16
Table (5)	Histology, precursors, and distinctive molecular features	23
Table (6)	Ovarian Cancer, Five-Year Stage-Specific Relative Survival Rates, Adults (Ages 15-99), Anglia Cancer Network, 2004-2008	26
Table (7)	Key pathways involved in the pathogenesis of epithelial ovarian cancer	36
Table (8)	Molecular alterations according to ovarian cancer subtype.	55
Table (9)	Targeted agents and their targets	60
Table (10)	Summary of results of the phase 3 trial comparing primary cytoreductive surgery to neoadjuvant chemotherapy followed by surgery in advanced ovarian cancer	68
Table (11)	Clinical trials of single-agent therapy with bevacizumab in ovarian cancer	81
Table (12)	Phase II bevacizumab trials in recurrent ovarian and primary peritoneal cancer	84

Table No.	Title	Page
Table (13)	Phase III bevacizumab trials in ovary cancer	88
Table (14)	Clinical trials for VEGF trap in ovarian cancer	92
Table (15)	Anti-VEGF agents in clinical development for ovarian cancer.	97
Table (16)	Summary of Potential targets of therapy in ovarian cancer	112
Table (17)	Incidence of grade 3/4 hypertension with antiangiogenic agents	116

List of Figures

Figure No.	Title	Page
Figure (1)	Ovarian Cancer (C56-C57), Number of New Cases per Year and Age-Specific Incidence Rates, UK, 2006-2008	8
Figure (2)	Different ovarian tumors originate from different cell subtypes. Prevalence of malignant components in parentheses	15
Figure (3)	Ovarian cancers in women aged 20+, with area representing relative incidence and color representing 5-year relative survival rate	17
Figure (4)	Pathological spiciment of ovarian carcinoma	18
Figure (5)	Serous ovarian carcinoma	19
Figure (6)	A low malignant potential mucinous ovarian tumour. H&E stain.	20
Figure (7)	Endometrioid carcinoma	21
Figure (8)	Clear cell carcinoma	22
Figure (9)	Pattern of spread of epithelial ovarian cancers.	24
Figure (10)	The five-year relative survival rates for ovarian cancer in England during 2005-2009 ranged from 87% in 15-39 year olds to 16% in 80-99 year olds	25
Figure (11)	Survival from ovarian cancer one-, three- and five-year survival post-diagnosis of ovarian cancer patients over the past 20 years	27

Figure No.	Title	Page
Figure (12)	Vascular endothelial growth factor (VEGF) family and their receptors	38
Figure (13)	VEGF-related family.	39
Figure (14)	Intercellular signaling among tumor cells, stroma cells, pericytes, and endothelial cells.	40
Figure (15)	A proposed model for intraperitoneal dissemination of ovarian cancer	41
Figure (16)	Signaling pathways and inhibitors of EGFR	43
Figure (17)	Role of Poly (ADP-ribose) polymerase in Base Excision Repair	45
Figure (18)	Synthetic Lethality of PARP Inhibition	46
Figure (19)	Repair of DSB by BRCA1 and BRCA2 proteins	46
Figure (20)	Molecular profile of serous ovarian cancer.	47
Figure (21)	The PI3K/Akt/mTOR signaling pathway	51
Figure (22)	Insuline receptors	57
Figure (23)	Folic acid metabolism	59
Figure (24)	Evolution of chemotherapy for ovarian cancer over the last 50 years	67
Figure (25)	CVac Fits in the Current Treatment Paradigm of Ovarian Cancer	75
Figure (26)	Comparison of the Kaplan–Meier curves for PFS between GOG218 and the high-risk subgroup of ICON7	87
Figure (27)	Diffuse erythematous dermatologic rash	135

Introduction

Ovarian cancer is the fifth cause of cancer related death in women, the second most common gynecological cancer and the leading cause of death from gynecological malignancies. Although it may arise from all cell types composing the ovaries as primary tumors of epithelial, sex cord-stromal, or germ cell origin and metastatic tumors that frequently originate in the gastrointestinal tract, the epithelial carcinomas are by far the most common (85-90% of all ovarian cancer) (**Kurman et al., 2010**).

Risk factors include nulliparity, early menarche, late menopause, age and strong family history of breast and ovarian cancer. About 10 % to 15% of woman with ovarian cancer has genetic predispositions of BRCA1 and BRCA2 mutations (**Gayther et al., 2010**).

Ovarian cancer is one of the least detectible cancers because vague symptoms such as fatigue, abdominal swelling or discomfort, trouble eating or frequent urination. So early detection of cancer patients remains an important objective in the field because over 70% of patients are diagnosed at late stage disease, with dissemination of tumor implants throughout the peritoneal cavity (**Hennessy et al., 2009**).

Only 10-15% of these patients maintain a complete response to the initial therapy .The five-year survival of patients that present with late stage disease, which is the case for most patients, remains at < 30% with a mean survival of 39 months (**Cho et al., 2009**).

Treatment options and recommendations depend on several factors, including the type and stage of cancer, possible side effects, the patient's preferences and personal considerations, such as the woman's age, planning to have children and the sexual function (**Van Nagell et al., 2011**).

The current standard treatment for advanced ovarian cancer consists of cytoreductive (debulking) surgery, usually a bilateral salpingo-oophorectomy (removal of the ovaries and fallopian tubes) and hysterectomy are performed. The surgeon may also remove the omentum to determine whether the cancer has spread. Also remove lymph nodes, tissue samples, and fluid from the abdomen (**Safra et al., 2011**).

Chemotherapy as Paclitaxel combined with platinum-based regimen is the standard first-line chemotherapy used for all patients with ovarian cancer. Although clear cell type is categorized in indolent type, it is known to show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to serous adenocarcinoma, especially in advanced stages. Irinotecan plus cisplatin therapy may be effective for the clear cell adenocarcinoma (**Monk et al., 2010**).

Intraperitoneal chemotherapy possibly improve progression-free and overall survivals (PFS and OS). However, it has not been universally accepted for the toxic effects and intraperitoneal complications (**Pujade-Lauraine et al., 2010**).

Radiation treatment is not usually used to treat ovarian cancer, but it may be used to relieve side effects. Which depend on the dose and the area of the body being treated, but may include fatigue, mild skin reactions, upset stomach, and loose

bowel movements. Side effects of internal radiation therapy may include abdominal pain and bowel obstruction. Most side effects usually go away soon after treatment is finished (Vencken et al., 2011).

Recurrence is associated with incurable diseases in most cases. Thus, the main obstacle to an effective treatment is the failure of the initial chemotherapy to eradicate a sufficient number of tumor cells to prevent disease recurrence. In this context, deficiency in the apoptotic cascade among tumor cells is the key hallmark (Vergote et al., 2010).

Improved prognosis in ovarian carcinoma is related to the use of the new biological agents. One of the most investigated and promising molecular targeted drugs in ovarian cancer is **bevacizumab**, a monoclonal antibody directed against VEGF. A recent study demonstrated positive results of bevacizumab on progression-free survival in ovarian cancer patients. Two phase III trials have recently evaluated the role of bevacizumab in first-line chemotherapy as an adjunct to carboplatin and paclitaxel (Katsumata et al., 2012). Other molecular target therapies include EGFR tyrosine kinases, HER2 receptor, PARP inhibitors. Multiple PARP inhibitors in development trials (Olaparib, Veliparib, Rucaparib, BMN 673, others). Trials combining PARP inhibitors with chemotherapy (Yoshino et al., 2012).

A phase III study of **farletuzumab** in combination with carboplatin and a taxane in patients with platinum-sensitive epithelial ovarian cancer in first relapse. The study did not meet the study's primary endpoint of progression-free survival (PFS).